INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

Pomerantz LLP announced it is investigating potential claims on behalf of investors of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). The notice, dated Oct. 8, 2026, says the inquiry concerns whether the company and certain officers and/or directors may have engaged in securities fraud or other unlawful business practices. It cites a Sept. 24, 2026 press release announcing Phase 3 enabling topline results from the RADIANT program’s Phase 2 portion for remlifanserin in hallucinations and delusions associated with Alzheimer’s disease psychosis. The company disclosed the 60 mg dose “narrowly missed” the primary endpoint. After the Sept. 24 drop of $3.25 per share (12.78%) to close at $22.18, multiple analysts downgraded the stock on Sept. 25, leading to another decline of $1.50 (6.76%) to $20.68.